Preview Newsletter
XARELTO Media Monitoring – Week of 03-03-16
-
Xarelto Lawsuit Plaintiffs Gain Support From Studies Connecting Drug Use To Dangerous Bleeding Episodes
Feb 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on important results gained from multiple studies which have brought up fresh concerns over the public use of anticoagulant Xarelto by connecting it to sudden and dangerous bleeding episodes in patients. This supports the arguments of many lawsuit plaintiffs who have stepped forward filing lawsuits against Xarelto manufacturers Janssen Pharmaceuticals and Bayer AG, all who similarly allege that the anticoagulant puts users at increased risk for serious and even fatal bleeding side effects. -
Xarelto Litigation — An Update
Feb 29, 2016 | Searcy Denney
By Brenda Fulmer
On February 23, 2016, Judge Fallon held another status conference in the national litigation over Xarelto. There are now over 5,600 individual lawsuits pending in MDL No. 2952, the coordinated federal court proceedings pending in New Orleans. There thousands of lawsuits have been filed against pharmaceutical giants Bayer Corporation and Johnson & Johnson and their various domestic and foreign subsidiaries that participated in the design, manufacturing, and marketing of Xarelto, a popular blood thinner. -
Xarelto Lawsuit Plaintiff Alleges Blood-Thinning Drug Caused Life-Threatening Internal Bleed
Feb 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG. The suit was initially filed in the Eastern District of New York, but has since been transferred with the formation of MDL No.2592 in Louisiana. It was filed by a Texas woman who claims that the defendants neglected to warn physicians and patients (including herself) about the possible dangerous side effects associated with their anticoagulant drug. In New York, her lawsuit was filed under case number 1:14-cv-04524. -
A Xarelto Bleeding Lawsuit Overview: Current Updates On MDL No. 2592 From Louisiana
Mar 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the latest details concerning anticoagulant drug Xarelto and the mounting lawsuits now surrounding it. Xarelto gained approval by the U.S. Food and Drug Administration in 2011, and was released to the market just after this. To the public, as a new-generation blood thinning drug, Xarelto was considered to be a revolutionary treatment, offering patients more freedoms than other blood thinners had in the past. It was primarily used to treat patients with deep vein thrombosis and pulmonary embolism, and to prevent issues such as strokes or blood clots for patients recovering from recent hip and knee replacement surgeries. -
Xarelto Lawsuit Plaintiffs Gain Support From JAMA Ophthalmology Studies Which Link Drug To Spontaneous Bleeding Episodes
Mar 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerhelp.com reports on the results of multiple studies which highlight new questions surrounding the safety of new-generation anticoagulant drug Xarelto. The blood thinner is produced by manufacturers Bayer Healthcare and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson). The studies appear to link the drug to an elevated risk of dangerous bleeding episodes, including stomach, eye, and brain, hemorrhages for patients taking it. Plaintiffs involved in current Xarelto lawsuits find support from this data-based information. -
Xarelto Lawsuit Claims Drug Caused Severe Gastrointestinal Bleed Of Ohio Woman
Mar 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) in regards to their new-generation anticoagulant drug, Xarelto. The plaintiff involved in the lawsuit, a woman from Ohio, alleges that the blood thinner caused her sudden and serious gastrointestinal bleeding incident. -
Vermont Xarelto Lawsuit Plaintiff Claims Anticoagulant Drug Caused Fathers Death
Mar 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Xarelto manufacturers Bayer AG and Janssen (a division of Johnson & Johnson corporation). The suit was initially filed in Vermont under case number 2:14-cv-00159-CR in the state’s federal court. It was filed by a young woman on behalf of her deceased father after he passed away due to uncontrollable bleeding. Her complaint, which has now been transferred to join other similar cases in multidistrict litigation number 2592, claims that the anticoagulant drug Xarelto caused the father’s sudden, uncontrollable bleeding episode, as well as his subsequent death. -
Xarelto Lawsuit Plaintiffs Claim Blood Thinner Caused Severe And Lasting Side Effects
Mar 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG. The plaintiffs who filed this lawsuit in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-06514, are a married couple from Nebraska who commonly claim that the defendants manufactured an unsafe medication. Additionally, they allege that because of the husband’s use of Xarelto, he currently suffers from severe and long-term side effects following a dangerous uncontrollable bleeding episode. The couple also states that because of this, the man’s life expectancy has now been shortened. -
BMJ Study Shows Possible Twofold Increase In GI Bleeding Risk GIving Support To Xarelto Lawsuit Claims
Mar 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the results of several drug studies which suggest a link between anticoagulant drug Xarelto and an elevated risk of sudden and dangerous bleeding episodes among patients, such as spontaneous vitreous hemorrhages (eye bleeds), stomach bleeds, brain bleeds, gastrointestinal bleeds, and others. These results cause new concerns over the drug but help to support plaintiffs currently involved in the Xarelto multidistrict litigation or mass tort group. -
Xarelto Lawsuit Plaintiffs Allege Anticoagulant Caused Serious And Permanent Side Effect
Mar 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG in reference to Xarelto, the anticoagulant drug they manufacture. The plaintiffs filing this complaint, which was filed in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-06514, are a husband and wife from Nebraska who allege that Bayer and Janssen manufactured an unsafe drug. They also allege that because he took Xarelto, the husband now suffers from serious and lasting side effects after experiencing a sudden uncontrollable bleeding episode. Additionally, they say the man now has a shortened life expectancy. -
New Orleans Xarelto Lawsuit Attorneys Mantes-La-Jolie
Feb 26, 2016 | Mantes-La-Jolie
Xarelto, one of many present day drugs to assist sufferers affected by blood clotting, was authorized for commercial launch in 2011. It is manufactured by well-recognized pharmaceutics company, Bayer and marketed by Janssen Pharmaceuticals, an entirely-owned subsidiary of Johnson & Johnson (NYSE:JNJ). Every part was going well for Bayer and Xarelto till stories about Xarelto inflicting uncontrollable internal bleeding began pouring in. -
Xarelto Lawsuit Timeline
Feb 26, 2016 | Jones Ward
The history of the blood-thinner Xarelto can be confusing to understand. If you think you or someone you love has been harmed by the drug, you’re probably wondering why it happened or if it could’ve been prevented. This Xarelto lawsuit timeline will show you that there were plenty of opportunities for the makers of Xarelto to notice that their drug could be harmful and amend their marketing techniques accordingly. However, they chose not to. -
Number Of Xarelto Prescriptions Expected To Increase Despite Bleeding Risks
Feb 26, 2016 | Righting Injustice
By Jennifer Walker-Journey
More doctors will be prescribing and more patients using novel oral anticoagulants (NOACs) such as Xarelto instead of the long-used warfarin, according to an analyst with the research and consulting firm GlobalData. -
Xarelto Lawsuits at 3,000 and Counting in Just Five Years
Feb 26, 2016 | LawyersandSettlements
By Gordon Gibb
It was in July 2011 that the US Food and Drug Administration (FDA) approved Xarelto (Rivaroxaban) as a long-awaited successor to the 50-year-old Coumadin (warfarin), the standard for blood thinning for a half-century. While warfarin is not infallible (no drug is), any litigation involving the latter over its tenure on the market pales in comparison to the 3,000-plus plaintiffs having filed a Xarelto Lawsuit in the five years since Xarelto appeared on the scene. -
Xarelto Lawsuit Plaintiffs Share Their Concerns For Chris Bosh
Feb 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
The NBA team the Miami Heat may once again find themselves short one of their stars if physicians believe that Chris Bosh shouldn’t return to the court. -
Xarelto Caused Gastrointestinal Bleeding, Lawsuit Says
Mar 2, 2016 | Top Class Actions
By Ashley Vanover
Although Xarelto was approved for use in 2011 and is one of the newest blood thinners on the market, it is already the subject of claims and litigation carrying allegations that the blood thinner puts patients at risk for dangerous side effects, including life-threatening internal bleeding. -
Xarelto® (Rivaroxaban) & Bleeding Lawsuits
Mar 2, 2016 | Peterson and Associates
Xarelto® (rivaroxaban) is a medication jointly produced by pharmaceutical giants Bayer and Johnson & Johnson. The drug was released to the market in 2011 and the FDA approved it as a blood-thinner that is used to treat patients in danger of experiencing strokes. -
Monsanto Roundup Lawsuit Alleges Non-Hodgkin’s Lymphoma Diagnosis Caused by Exposure
Mar 3, 2016 | AboutLawsuits.com
By Irvin Jackson
A farm worker diagnosed with non-Hodgkin lymphoma following Roundup exposure has filed a product liability lawsuit against Monsanto, alleging that the multinational agricultural biotechnology corporation withheld information about the cancer risks associated with their popular herbicide. -
Xarelto Side Effects & Lawsuit Information
Mar 3, 2016 | Active Health News
Xarelto is a blood-thinning drug, or anticoagulant. The U.S. Food and Drug Administration (FDA) approved Xarelto in July 2011, and its sales have steadily grown since then. While bleeding is a common complication associated with anticoagulants, it has been alleged that Xarelto is more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning side effects.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Feb 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on important results gained from multiple studies which have brought up fresh concerns over the public use of anticoagulant Xarelto by connecting it to sudden and dangerous bleeding episodes in patients. This supports the arguments of many lawsuit plaintiffs who have stepped forward filing lawsuits against Xarelto manufacturers Janssen Pharmaceuticals and Bayer AG, all who similarly allege that the anticoagulant puts users at increased risk for serious and even fatal bleeding side effects.
The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011. It was initially approved to treat patients at increased risk of developing blood clots or having strokes. Additionally, it was intended to be given to individuals recovering from knee and hip replacement surgeries, and those suffering from pulmonary embolism or deep vein thrombosis. Shortly after its initial approval, Xarelto’s approved treatments were expanded to include patients who suffered from atrial fibrillation.
Increasing talks of dangerous side effects linked to Xarelto spurred doctors Judy Hun and John Hwang to further investigate the anticoagulant’s effects on their own patients. They found that within their own practice, they began to notice that some of their patients had developed “spontaneous vitreous hemorrhage” (or sudden eye-bleeding) while using Xarelto. After studying this possible link, the medical team found that risks of these eye bleeding occurrences may be elevated; especially among patients who had transitioned from taking traditional blood thinners to taking Xarelto.
Unfortunately, this study is not the only one to have linked Xarelto use by patients to an increased risk of sudden bleeding episodes. Another study, which ran from October 1, 2010, to March 31, 2012, evaluated thousands of patients from across the U.S. who had taken either Xarelto, Pradaxa, or warfarin blood thinners. While observing a large sample of 46,000 patients, 39,607 of whom used warfarin, 4,907 of whom used Pradaxa, and 1,649 of whom used Xarelto, results showed “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”
Today, lawsuit numbers filed against Xarelto manufacturers have surpassed 2,800 cases in federal court, and include an additional 550 or more cases which have formed a mass tort group in Philadelphia, Pennsylvania. All federally-filed cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form MDL number 2592 in Eastern Louisiana, and are currently being overseen by Judge Eldon Fallon.
At this time, Attorney Joseph Osborne is working to assist anyone who has taken Xarelto and has also suffered from health problems that they link to the drug. It is believed that these individuals may be entitled to legal action and substantial compensation. Because everyone deserves the important opportunity to explore their legal rights in full, Attorney Osborne is helping to facilitate this process by offering free legal consultations to those affected.
To obtain additional information on Xarelto bleeding lawsuits, or to ask questions, please call Attorney Osborne at (866) 425-8902.
http://www.digitaljournal.com/pr/2852960#ixzz41svy5yRp
-
Xarelto Litigation — An Update
Feb 29, 2016 | Searcy Denney
By Brenda Fulmer
On February 23, 2016, Judge Fallon held another status conference in the national litigation over Xarelto. There are now over 5,600 individual lawsuits pending in MDL No. 2952, the coordinated federal court proceedings pending in New Orleans. There thousands of lawsuits have been filed against pharmaceutical giants Bayer Corporation and Johnson & Johnson and their various domestic and foreign subsidiaries that participated in the design, manufacturing, and marketing of Xarelto, a popular blood thinner.
Xarelto (also known as rivaroxaban) was approved by the FDA in 2011 as a part of a new class of blood thinners prescribed to patients. This class of drug is prescribed to patients with atrial fibrillation to prevent strokes and to surgical patients to prevent post-operative blood clots in their legs and lungs. Xarelto is used by physicians as an alternative to warfarin (also known as Coumadin), which has been used in patients for over 60 years.
Xarelto National Litigation
Xarelto was approved by the Food & Drug Administration in 2011 and was somewhat controversial. The FDA’s own internal medical reviewers were concerned about the validity of the single study used as the basis for the drug’s approval by the FDA (an issue now at the heart of the Xarelto litigation and discovery efforts). As aggressively touted in direct-to-consumer TV ads, patients who ingest Xarelto do not require the same routine blood testing as patients taking Coumadin. This “easy button,” however, may come at great cost. There are reports the incidence of adverse events associated with Xarelto are higher than those seen in patients taking Coumadin.
The thousands of Xarelto lawsuits filed so far nationally focus on the lack of a reversal treatment for Xarelto. The advantage to Coumadin is that vitamin K or packed red blood cells can reverse the effects of Coumadin within a few hours of administration, but that treatment does not work with Xarelto and patients are at risk of life threatening and uncontrolled bleeding. Patients should have been tested to determine whether their bodies can properly process Xarelto prior to administration of the drug and this would likely have prevented thousands of patients’ injuries due to Xarelto-induced blood clots (which led to GI bleeds, cardiac tamponade, intracranial hemorrhaging, and death).
Besides the thousands of lawsuits pending in MDL No. 2952 in Louisiana, there are also hundreds of individual lawsuits filed in state courts in New York, Delaware, California, and Pennsylvania. Recently, an application was filed requesting that a Judicial Council Coordinated Proceedings (“JCCP”) be established in state court for the coordination of Xarelto lawsuits in that state. There are 18 individual lawsuits filed in California, with many additional case filings expected if the statewide coordination is granted by the California judge.
At the February MDL Status Conference, Judge Fallon was provided with an extensive update regarding progress, including the exchange of case-specific discovery information including:
Damage issues
Medical histories
Plaintiffs’ personal histories
Xarelto sales force communications with prescribing physicians
Adverse event reports to the FDA and
Payments made to prescribers and consultants
Judge Fallon will hold additional hearings in March on the Defendants’ requests to dismiss several cases for failure to serve completed discovery information within the aggressive timetable established for the Xarelto litigation.
There are several depositions underway in New Jersey, Pennsylvania, and Amsterdam involving Bayer and Janssen’s employees. Judge Fallon’s recent Pretrial Order provides further guidance to the parties on the rules relating to depositions. It is hoped the order will help to streamline this process, especially in light of the tremendous time and expense associated with taking so many depositions of corporate witnesses in Europe. Besides this latest order, Judge Fallon has issued 30 additional orders covering all aspects of the coordination and management of this multi-district litigation since MDL No. 2592 was first established in December of 2014.
Judge Fallon also heard arguments from both sides at the February 2016 hearing regarding the Defendants’ requesting it be allowed to have direct contact with plaintiffs’ treating physicians. The Defendant contends that it should be permitted to consult directly with the Plaintiffs’ treating physicians. Typically and in compliance with HIPPA rules the Defendants may not engage in ex partecommunications with the Plaintiffs’ treating or prescribing physicians about a particular Plaintiff’s treatment or about issues relating to the ongoing litigation. Instead, Defendants must obtain information about the Plaintiffs’ condition or other issues relating to the lawsuit through a deposition, where the Plaintiff’s attorney is present and the questions and answers are recorded by a court reporter. Judge Fallon has taken this issue under consideration and is expected to issue an order shortly.
It has now been over 10 months since the Plaintiffs’ Steering Committee issued a subpoena to the Food & Drug Administration (FDA) seeking critical information regarding the Agency’s approval of Xarelto following a single clinical trial. So far, the FDA has produced a list of documents associated with the drug application for Xarelto, but has not yet turned over the critical and substantive documents. Unfortunately, it is far too common for the FDA to refuse to expeditiously produce safety information over approved drugs and medical devices during litigation. The FDA has also historically fought any attempts to obtain deposition testimony from its employees regarding drug approval, regulation of drug companies, recalls, and adverse event reporting.
On February 22, 2016, the New York Times published an article detailing one of the major discoveries in the Xarelto litigation. The FDA is investigating whether the clinical trial used as the basis for the FDA’s approval of Xarelto may have been fatally flawed due to use of a defective blood testing device. According to the newspaper reports, internal documents uncovered in the Xarelto litigation indicate that doctors involved in the ROCKET AF clinical study (which included 14,000 patients and spanned from 2006 to 2010) were reporting critical issues to the drug companies during the study. Judge Fallon has reportedly been asked to unseal documents relating to this controversy produced in the MDL litigation but are subject to a protective order.
The issue is particularly politically-charged since the ROCKET AF drug study for Xarelto was led by Dr. Robert M. Califf (a former director of Duke Clinical Research Institute), who is President Obama’s nominee to be the new leader of the FDA and serves as the FDA’s deputy commissioner.
There is speculation that the malfunction of the device that measured INR levels in patients in the Coumadin portion of the clinical study could have led to study participants receiving the wrong dose of warfarin. This could lead to there being a higher incidence of strokes due to receiving an insufficient dose of Coumadin and bleeding episodes due to receiving too much Coumadin in the control patients who took Coumadin. The effect of this would be to make Xarelto appear more effective and safer than may be true. The FDA is delving deeper into these critical safety issues.
Duke Clinical Research, the group that oversaw the ROCKET AF study, recently published an article in the New England Journal of Medicine contending that using the faulty (and now-recalled) blood testing device did not affect the clinical trial’s ultimate results. The European Medicines Agency has reached a similar result. According to the New York Times, however, these conclusions should not prevent further inquiry; especially since tests were done during the course of the study that “could have been used to assess whether the devices’ readings were accurate.” The New York Times was also critical of the EMA article and its reliance on data supplied solely by the drug companies and not independent researchers.
Johnson & Johnson contends that it did not learn about the accuracy of readings from the medical device manufactured by Allere or the recall of the device until September of 2015. In December of 2015, an article was published in the British Medical Journal regarding the need to re-analyze the ROCKET AF data due to the use of an alleged faulty testing device. According to media reports, the INRatio blood measuring device used in the study had faced scrutiny from the FDA going back to 2005 and 2006. It is reported the manufacturer of the device received warning letters from the FDA regarding inaccuracies in the medical device’s reporting of blood results and the manufacturer’s failure to properly investigate and report safety issues.
http://www.jdsupra.com/legalnews/xarelto-litigation-an-update-25117/
-
Xarelto Lawsuit Plaintiff Alleges Blood-Thinning Drug Caused Life-Threatening Internal Bleed
Feb 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG. The suit was initially filed in the Eastern District of New York, but has since been transferred with the formation of MDL No.2592 in Louisiana. It was filed by a Texas woman who claims that the defendants neglected to warn physicians and patients (including herself) about the possible dangerous side effects associated with their anticoagulant drug. In New York, her lawsuit was filed under case number 1:14-cv-04524.
Documents for this lawsuit show that the woman claims to have been prescribed Xarelto by her physician in order to prevent the occurrence of a stroke. She was at increased risk for this occurrence because of her atrial fibrillation condition. She also stated that she had only been using the blood thinner for 5 month’s time when she suffered from a sudden internal bleed which physicians termed life-threatening. Though she considers herself lucky to have survived this bleed, she claims that she will suffer with long-term medical needs because of it.
Xarelto received approval from the U.S. Food and Drug Administration in 2011 and successfully launched onto the market. It was a new-generation blood thinner, and one that suddenly required none of the physician monitoring, dietary restrictions, or dosage adjustments that other traditional blood thinners had. It became increasingly popular for these reasons. Xarelto was approved to treat patients recovering from hip and knee replacement surgeries, or those with pulmonary embolism and deep vein thrombosis. The approved uses were later expanded to include treatment for patients with atrial fibrillation, as a preventative measure for strokes.
Today, Xarelto lawsuits continue to be filed from across the nation, and number over 3,000. The Eastern Louisiana MDL contains over 2,800 cases consolidated by the U.S. Judicial Panel on Multidistrict Litigation, while another group of more than 550 lawsuits have been consolidated to form a mass tort in Philadelphia, Pennsylvania. All plaintiffs share common allegations that the blood thinner puts users at increased risk for sudden dangerous bleeding episodes.
As the plaintiffs wait for these cases to progress, case numbers steadily increase. Attorney Joseph Osborne is working to help ensure that anyone who feels that they have suffered health problems from using the blood thinner will have the opportunity to fully investigate their legal rights. Patients who used Xarelto and who suffered from health problems which they attribute to taking the drug may be entitled to significant compensation. To help those interested in pursuing justice, Attorney Osborne is currently offering free legal consultations for qualifying individuals.
To request further information on Xarelto lawsuits, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2851090#ixzz41svZzHwU
-
A Xarelto Bleeding Lawsuit Overview: Current Updates On MDL No. 2592 From Louisiana
Mar 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the latest details concerning anticoagulant drug Xarelto and the mounting lawsuits now surrounding it. Xarelto gained approval by the U.S. Food and Drug Administration in 2011, and was released to the market just after this. To the public, as a new-generation blood thinning drug, Xarelto was considered to be a revolutionary treatment, offering patients more freedoms than other blood thinners had in the past. It was primarily used to treat patients with deep vein thrombosis and pulmonary embolism, and to prevent issues such as strokes or blood clots for patients recovering from recent hip and knee replacement surgeries. Later as well, these approved uses were expanded to include treatment for patients with atrial fibrillation condition.
The drug has become, however, the subject of great public controversy, and more than 3,000 lawsuits across the nation. More than 2,800 of these cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL 2592, while another group of over 550 cases have been consolidated to form a mass tort group in Pennsylvania.
Xarelto’s label now includes two black box warnings from the FDA. These are the most severe warnings a product can be given before it is completely removed from the market. These particular warnings indicate an elevated risk of blood clot formation for patients who suddenly discontinue use of the drug without slowly weaning off of it and onto another anticoagulant.
There is another dangerous issue, however, that is most commonly mentioned by plaintiffs who have filed lawsuits against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). The vast amount of plaintiffs involved in these cases similarly claim that the anticoagulant can put users at heightened risk for sudden, dangerous bleeding episodes, including eye, stomach, and brain bleeds. Plaintiffs believe that the drug’s manufacturers hid these potential risks and instead used misleading product marketing tactics to promote their drug.
All cases involved in MDL 2592 are being overseen in New Orleans, Louisiana. The court has noted that it will hold four bellwether trials discussing the drug beginning in February of 2017. In the meantime, as the many plaintiffs involved await trial dates, Attorney Joseph Osborne is working to ensure that anyone who believes they were negatively affected by Xarelto will be afforded the opportunity to explore their legal options in full. These patients could be entitled to substantial compensation. To help encourage those in need to pursue the justice they deserve, Attorney Osborne is offering complimentary legal consultations for qualifying individuals at this time.
To request additional information, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.
http://www.wrcbtv.com/story/31360972/a-xarelto-bleeding-lawsuit-overview-current-updates-on-mdl-no-2592-from-louisiana
-
Mar 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerhelp.com reports on the results of multiple studies which highlight new questions surrounding the safety of new-generation anticoagulant drug Xarelto. The blood thinner is produced by manufacturers Bayer Healthcare and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson). The studies appear to link the drug to an elevated risk of dangerous bleeding episodes, including stomach, eye, and brain, hemorrhages for patients taking it. Plaintiffs involved in current Xarelto lawsuits find support from this data-based information.
One of these supportive studies was completed by Doctors John C. Hwang and Judy H. Hun after they noticed that several Xarelto patients in their practice were suffering from sudden bleeding episodes. They did some research, and found that patients aged 70-89 who had previously used warfarin (a traditional blood thinning drug) and who had later switched to take Xarelto, were at elevated risk for suffering from vitreous hemorrhages, or eye bleeds. These eye bleeds specifically occur between the lens and retina of the eye. Testing by the physicians appeared to confirm that users who had transitioned from traditional blood thinners to Xarelto were at heightened risk of this occurring.
An additional study, published in the April 2015 issue of BMJ indicated that results could not rule out a twofold increased risk of stomach bleeding episodes for consumers taking Xarelto when compared to those taking warfarin. To come to these results, this study observed almost 46,000 patient’s medical records.
These studies help to lend supportive arguments to over 2,800 plaintiffs who have filed federal lawsuits against Xarelto manufacturers. They all commonly allege that Xarelto use caused them to suffer from dangerous and uncontrollable bleeding episodes. Some plaintiffs are even representing loved ones who they say passed away due to such severe uncontrollable bleeds.
As these many lawsuit plaintiffs await their day in trial, Attorney Joseph Osborne is working to help ensure that anyone who has taken Xarelto and has since suffered from health problems will be afforded the opportunity to fully investigate their legal rights. In order to help those deserving pursue justice, Attorney Osborne is offering free Xarelto consultations at this time. Those affected may be entitled to substantial compensation.
To ask questions, or to request more information on Xarelto bleeding lawsuits, please contact Attorney Osborne by calling (866) 425-8902.
http://www.newswest9.com/story/31360950/xarelto-lawsuit-plaintiffs-gain-support-from-jama-ophthalmology-studies-which-link-drug-to-spontaneous-bleeding-episodes
-
Xarelto Lawsuit Claims Drug Caused Severe Gastrointestinal Bleed Of Ohio Woman
Mar 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) in regards to their new-generation anticoagulant drug, Xarelto. The plaintiff involved in the lawsuit, a woman from Ohio, alleges that the blood thinner caused her sudden and serious gastrointestinal bleeding incident.
In further details of her case within court documents, the woman explained that she was provided a prescription for the anticoagulant from her doctor as a preventative treatment for the development of possible blood clots or strokes, which she was deemed at increased risk for due to her atrial fibrillation condition.
Atrial fibrillation is a fairly common heart condition which generally makes the heart beat faster than what is considered normal. The plaintiff indicates that she took Xarelto for less than one year’s time when she suddenly developed a dangerous and severe gastrointestinal bleed. She claims, as many other plaintiffs from across the nation have, that the bleed was caused by her use of Xarelto.
In 2011, Xarelto was given approval by the U.S. Food and Drug Administration, and it quickly became popular on the market, as it was able to provide users with many freedoms that other more traditional blood thinners had been unable to. Still today, Xarelto is the only blood thinner to offer one pill per day and one-size-fits-all dosing.
Despite these initial popular traits, however, many consumers have now switched their views concerning the blood thinner, and have come to consider Xarelto as the most dangerous blood thinner currently on the market. The drug has also been given two ‘black box’ warnings from the FDA, which are the most severe warnings able to be placed on a product before it is completely pulled from the market.
At this time, over 2,800 Xarelto lawsuits have been federally-filed, and have been consolidated by the U.S. JPML to form multidistrict litigation number 2592. Many anticipate that as these plaintiffs await trial, others will also file suit. Attorney Joseph Osborne is helping to ensure that anyone who suffered from health problems that they attribute to the blood thinner will be provided the opportunity to investigate their legal rights in full. Patients who believe they were affected by the drug may be entitled to significant compensation. To encourage those deserving to pursue justice, Attorney Osborne is currently offering complimentary legal consultations.
To obtain further information on Xarelto lawsuits, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.kxxv.com/story/31360967/xarelto-lawsuit-claims-drug-caused-severe-gastrointestinal-bleed-of-ohio-woman
-
Vermont Xarelto Lawsuit Plaintiff Claims Anticoagulant Drug Caused Fathers Death
Mar 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Xarelto manufacturers Bayer AG and Janssen (a division of Johnson & Johnson corporation). The suit was initially filed in Vermont under case number 2:14-cv-00159-CR in the state’s federal court. It was filed by a young woman on behalf of her deceased father after he passed away due to uncontrollable bleeding. Her complaint, which has now been transferred to join other similar cases in multidistrict litigation number 2592, claims that the anticoagulant drug Xarelto caused the father’s sudden, uncontrollable bleeding episode, as well as his subsequent death.
In case details, the daughter explains that her father was prescribed Xarelto by his doctor as a treatment for his atrial fibrillation condition. Atrial fibrillation is a common heart condition which can cause the heart to beat more rapidly than what is considered normal. The condition puts patients at increased risk for strokes, so many of those with atrial fibrillation take blood thinning medications preventatively.
After taking the medication for just a short time, the father was reportedly injured and hospitalized. At the hospital, it was noted that he had suffered from a parenchymal hemorrhage (or brain bleed) and that physicians were unable to clot and stop the bleed. Because the man had active Xarelto in his system at the time, stopping the bleed proved to be too difficult, and after 6 full days of substantial blood loss, the man passed away.
At the time of the man’s death, Xarelto was given to patients without any available antidote provided by the manufacturer. This means that when patients using the drug became injured and bled, it was incredibly difficult to stop those bleeds, and they could easily become fatal. Traditional blood thinners were released to market with a corresponding antidote immediately, so patients taking these drugs who were injured and bleeding could be treated with that antidote (vitamin K), allowing their blood to clot and potentially saving their life.
Xarelto lawsuits filed from across the nation continue to increase in number, and currently amount to around 3,300. Over 2,800 of these filings have been consolidated to form multidistrict litigation number 2592, while the other 550 of more have become part of a mass tort group in Philadelphia, Pennsylvania.
As the plaintiffs involved await further litigation progress, many expect that other lawsuits will continue to be filed against the drug. Attorney Joseph Osborne is currently working to help ensure that everyone who used Xarelto and who suffered from health problems that they associate with their use of the drug will be given the important opportunity of evaluating their legal rights in full. These patients may be entitled to legal action and substantial compensation. At this time, Attorney Osborne is offering complimentary consultations for affected parties.
To request more information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.kxnet.com/story/31372073/vermont-xarelto-lawsuit-plaintiff-claims-anticoagulant-drug-caused-fathers-death
-
Xarelto Lawsuit Plaintiffs Claim Blood Thinner Caused Severe And Lasting Side Effects
Mar 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG. The plaintiffs who filed this lawsuit in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-06514, are a married couple from Nebraska who commonly claim that the defendants manufactured an unsafe medication. Additionally, they allege that because of the husband’s use of Xarelto, he currently suffers from severe and long-term side effects following a dangerous uncontrollable bleeding episode. The couple also states that because of this, the man’s life expectancy has now been shortened.
Additional details found in court documents state that the husband took Xarelto for 7 months in 2013, from May through December. In December, he suddenly suffered from a gastrointestinal bleeding event. The couple claims that this serious bleed was initiated by the blood thinner. Unfortunately, the doctors struggled to clot the man’s blood, as Xarelto was in his system at the time, and an antidote for the drug had not yet been developed.
The plaintiffs in this lawsuit are joined by many others from across the country who share common allegations against the same defendants. Xarelto has recently become the subject of thousands of lawsuits which claim that the anticoagulant puts patients at increased risk for the development of serious and sudden bleeding episodes. Xarelto lawsuits filed in federal courts across the U.S. have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. The MDL now holds over 2,800 cases and is located in Eastern Louisiana. These cases are additionally joined by another group of over 550 which have formed a mass tort group in Philadelphia, Pennsylvania.
By filing suit, the plaintiffs in this particular case are seeking compensatory and punitive damages, and monetary compensation for legal fees incurred. Attorney Joseph Osborne is currently working to ensure that everyone who feels they may have been negatively affected by the blood thinner will be afforded the same opportunity to pursue justice. These patients may be entitled to legal action and significant compensation. To better assist those looking for justice, Attorney Osborne is providing complimentary legal consultations for affected parties at this time.
To request further Xarelto information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.hawaiinewsnow.com/story/31372061/xarelto-lawsuit-plaintiffs-claim-blood-thinner-caused-severe-and-lasting-side-effects
-
Mar 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the results of several drug studies which suggest a link between anticoagulant drug Xarelto and an elevated risk of sudden and dangerous bleeding episodes among patients, such as spontaneous vitreous hemorrhages (eye bleeds), stomach bleeds, brain bleeds, gastrointestinal bleeds, and others. These results cause new concerns over the drug but help to support plaintiffs currently involved in the Xarelto multidistrict litigation or mass tort group.
An estimated 3,300 Xarelto lawsuits have been filed across the U.S. Those filed in federal courts have been consolidated to form multidistrict litigation No. 2592 by the U.S. Judicial Panel on Multidistrict Litigation. These cases currently number around 2,800. In addition to these Xarelto lawsuits, however, there is another group of over 550 cases which has been formed into a mass tort group by the Court of Common Pleas in Philadelphia, Pennsylvania. Perhaps most striking is that all lawsuit plaintiffs share similar allegations and have stepped forward to file suit against defendants Bayer AG and Janssen Pharmaceuticals, (the manufacturers of Xarelto).
JAMA Ophthalmology published a very notable study in June of 2015 which highlighted a potential link between patient use of rivaroxaban (the generic form of Xarelto) and a heightened risk of the occurrence of sudden hemorrhaging episodes within the eyes. Researchers for this study concluded that “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.” These results are especially alarming for patients who have in fact switched from traditional blood thinners to new-generation blood thinner Xarelto.
Another concerning study linked potential bleeding health risks to Xarelto and was published in the April 2015 issue of BMJ. This study found that those taking Xarelto (rivaroxaban) could possibly double their risk of suffering from gastrointestinal bleeding events in comparison to patients taking warfarin (a traditional blood thinner). At the culmination of the study, researchers noted, “...we cannot rule out...a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”
In addition to the concerning results of these studies, Xarelto has also received two black box warnings from the U.S. Food and Drug Administration. This is the most serious and strict warning a product can be given before it is pulled entirely from the market.
For some time now, Attorney Joseph Osborne has observed the devastating effects of serious and even fatal bleeding episodes among patients, and he is currently working to assist those who have suffered from health problems that they link to their use of Xarelto. Attorney Osborne believes that victims are all entitled to the opportunity of fully exploring their legal rights. These patients may qualify for significant compensation. To assist those looking to pursue justice, Attorney Osborne is offering complimentary legal consultations for affected parties at this time.
To request further information on Xarelto bleeding lawsuits, or to ask questions, please contact attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2857692#ixzz41ssGZH7c
-
Xarelto Lawsuit Plaintiffs Allege Anticoagulant Caused Serious And Permanent Side Effect
Mar 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG in reference to Xarelto, the anticoagulant drug they manufacture. The plaintiffs filing this complaint, which was filed in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-06514, are a husband and wife from Nebraska who allege that Bayer and Janssen manufactured an unsafe drug. They also allege that because he took Xarelto, the husband now suffers from serious and lasting side effects after experiencing a sudden uncontrollable bleeding episode. Additionally, they say the man now has a shortened life expectancy.
Further details from the plaintiff’s lawsuit indicate that the husband used Xarelto for 7 months, from May through December of 2013, when he suddenly suffered a gastrointestinal bleeding episode. The couple alleges that this dangerous bleed was caused by his use of the blood thinner. Also, because the man had Xarelto in his system at the time of the bleed, and because Xarelto had no available antidote at the time, doctors had tremendous difficulty clotting his blood.
This couple, unfortunately, is not alone in their claims. Over the last few years, Xarelto has become the topic of thousands of lawsuits from across the nation, all which commonly claim that the drug puts users at heightened risk for dangerous bleeding episodes. All federally-filed Xarelto lawsuits have been consolidated by the JPML to form MDL No. 2592, which now includes over 2,800 cases. Additionally, over 550 other Xarelto lawsuits were filed in Philadelphia, Pennsylvania, and have been formed into a mass tort group there by the Court of Common Pleas.
These Nebraska lawsuit plaintiffs are seeking both compensatory and punitive damages, as well as compensation to cover legal fees. While they join the many other plaintiffs who await trials, Attorney Joseph Osborne is helping to ensure that anyone who feels they were negatively affected by Xarelto will have the same opportunity to pursue their own justice. These individuals may be entitled to substantial compensation. To help those deserving look into this option, Attorney Osborne is now providing free legal consultations for those affected.
To request additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2851347#ixzz41swRIlxq -
New Orleans Xarelto Lawsuit Attorneys Mantes-La-Jolie
Feb 26, 2016 | Mantes-La-Jolie
Xarelto, one of many present day drugs to assist sufferers affected by blood clotting, was authorized for commercial launch in 2011. It is manufactured by well-recognized pharmaceutics company, Bayer and marketed by Janssen Pharmaceuticals, an entirely-owned subsidiary of Johnson & Johnson (NYSE:JNJ). Every part was going well for Bayer and Xarelto till stories about Xarelto inflicting uncontrollable internal bleeding began pouring in.
To contact us for a free confidential seek the advice of, you can name us at (800) 277-1193 (toll free). You can also request a non-public and confidential consultation by clicking Free & Confidential Consult , which form will probably be immediately reviewed by one of our attorneys dealing with this litigation. Your group has been type, responsive and keen to go the additional mile when different regulation firms refused to take my case. My family and I admire all that you've finished for us. Now we are able to move on with our lives, thanks to you. In 2011, Xarelto (rivaroxaban) was approved for sale within the United States of America for the primary time.
August 12, 2014 - One other Xarelto lawsuit was filed in federal court docket in New York by a lady from Texas who developed extreme bleeding after taking the medicine for simply five months. August 21, 2014 - An extra lawsuit was filed towards Janssen Pharmaceuticals and Bayer alleging that Xarelto prompted a 92 12 months-outdated man to bleed to demise last 12 months. October 22, 2014 - The FDA issued a recall for about thirteen,500 bottles of Xarelto after receiving a customer complaint about contamination in a gross sales pattern. BE AWARE: Offering data for evaluation by an lawyer does not form an lawyer-shopper relationship.
According to an article posted on Drug Watch on February seventeenth, 2015 filed below Present Litigation & Lawsuit Information, the announcement was made that Bayer and J&J are seeking additional federal approvals for Xarelto for stroke sufferers, whilst circumstances are consolidated into MDL. You had been the one firm that acquired me funding regardless of the actual fact I bought a loan earlier in my case from a unique firm. Should have known as earlier, thank you for all of the onerous work.
In May 2014, the Institute for Protected Treatment Practices (ISMP) reported that medical doctors and patients were reporting hostile events linked to the usage of Xarelto in growing numbers. ISMP reported in QuarterWatch that there were 680 Xarelto antagonistic occasions reported within the U.S. in 2013. The number of experiences linked to Xarelto surpassed these linked to Pradaxa, which had as soon as held the dubious distinction of being the drug with the most opposed event reviews. DrugNews only recommends legal professionals who've already dealt with numerous blood thinning medicine cases and Xarelto lawsuits.
If you have any sort of questions pertaining to where and ways to make use of xarelto lawsuit commercial actress, you could contact us at our own site.http://postithost.com/index.php?page=item&id=11904
-
Feb 26, 2016 | Jones Ward
The history of the blood-thinner Xarelto can be confusing to understand. If you think you or someone you love has been harmed by the drug, you’re probably wondering why it happened or if it could’ve been prevented. This Xarelto lawsuit timeline will show you that there were plenty of opportunities for the makers of Xarelto to notice that their drug could be harmful and amend their marketing techniques accordingly. However, they chose not to. The timeline of Xarelto begins in late 2011:
November 2011
Xarelto is first approved by the FDA for the treatment of blood clots.
The first Xarelto-related death is reported to the FDA.
July 2011
Xarelto is approved by the FDA to treat deep vein thrombosis and pulmonary embolism.
June 2012
Physicians become concerned about Xarelto’s uncontrollable bleeding risks.
January 2013
Xarelto adverse event reports to the FDA exceed 600.
March 2013
Reports state that Xarelto has a 50% higher bleed risk than other similar drugs.
September 2013
Xarelto adverse event reports climb to nearly 1,000 in Germany.
February 2014
FDA denies Johnson & Johnson’s request to expand Xarelto’s uses.
June 2014
The first Xarelto lawsuit is filed in the U.S.
December 2014
Xarelto injury cases start to be consolidated.
July 2015
Number of consolidated Xarelto cases exceeds 800.
September 2015
Xarelto XANTUS study finds that the risk of major internal bleeding is 2% to 3% higher than for those not taking the drug.
October 2015
Number of consolidated Xarelto cases reaches nearly 1,700.
January 2016
The selection process for a Xarelto bellwether trial begins.
March-May 2017
Four bellwether trials will take place.Contact a Xarelto Lawyer
If you experienced major bleeding caused by Xarelto, you could be entitled to compensation. Thousands of people across the U.S. have been impacted by the harmful side effects of this dangerous blood-thinner. Our Xarelto attorneys at Jones Ward, PLC are actively investigating and monitoring these Xarelto lawsuits. Contact us today by filling out our free case evaluation or by calling us at 888-595-2922.
http://www.jonesward.com/xarelto-lawsuit-timeline/
-
Number Of Xarelto Prescriptions Expected To Increase Despite Bleeding Risks
Feb 26, 2016 | Righting Injustice
By Jennifer Walker-Journey
More doctors will be prescribing and more patients using novel oral anticoagulants (NOACs) such as Xarelto instead of the long-used warfarin, according to an analyst with the research and consulting firm GlobalData.
“NOACs are increasingly being used in patients with venous thromboembolism (VTE) due to the drugs’ rapid onset of action and the ability to be administered in fixed doses without the need for regular coagulation monitoring,” said Lakshmi Dharmarajan, Ph.D., a senior analyst for GlobalData overseeing Cardiovascular and Metabolic Disorders.
NOACs were first approved by the Food and Drug Administration (FDA) in 2010. There are now four blood thinners in this class currently on the market – Pradaxa, Xarelto, Eliquis and Savaysa. All are used to prevent strokes in patients with the irregular heart rhythm atrial fibrillation. Xarelto is also used to prevent or treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent blood clots in patients who recently underwent hip or knee replacement surgery.
The blood thinners were shown to be just as effective as warfarin at preventing blood clots, but the medications still posedbleeding risks such as gastrointestinal bleeds, brain bleeds and bleeding deaths. Until recently, unlike warfarin, there were no antidotes to reverse the bleeding effects of NOACs in the event of an uncontrolled bleeding episode. Last year, areversal agent was approved for Pradaxa. Antidotes for Xarelto and Eliquis are currently under review.
Because of the bleeding risk with no reversal agent to save patients in the event of a bleeding emergency, many doctors were hesitant to prescribe the newer blood thinners. When the new antidotes hit the market, doctors may become more comfortable with their patients taking the drugs.
In May 2014, the makers of Pradaxa paid $650 million to settle thousands of lawsuits waged by people who said they were not adequately warned of the bleeding risks with Pradaxa. Now, Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals face similar lawsuits with their NOAC Xarelto.
http://www.rightinginjustice.com/news/2016/02/26/number-of-xarelto-prescriptions-expected-to-increase-despite-bleeding-risks/
-
Xarelto Lawsuits at 3,000 and Counting in Just Five Years
Feb 26, 2016 | LawyersandSettlements
By Gordon Gibb
It was in July 2011 that the US Food and Drug Administration (FDA) approved Xarelto (Rivaroxaban) as a long-awaited successor to the 50-year-old Coumadin (warfarin), the standard for blood thinning for a half-century. While warfarin is not infallible (no drug is), any litigation involving the latter over its tenure on the market pales in comparison to the 3,000-plus plaintiffs having filed a Xarelto Lawsuit in the five years since Xarelto appeared on the scene.
To that end, the judge overseeing multidistrict litigation (MDL No. 2592 in the Eastern District of Louisiana) last month selected four bellwether cases that will go to trial a year from now, starting in February 2017.
According to reports, The Honorable Judge Eldon Fallon has scheduled those bellwether Xarelto Bleeding Issue trials for February 6, March 13, April 24 and May 30 of 2017 respectively. Various plaintiffs allege that use of Xarelto fostered Xarelto Bleeding complications due to the lack of an antidote and claims by the manufacturer that Xarelto did not require the kind of stringent monitoring normally undertaken with Coumadin.
For years, doctors and patients had been looking for an easier alternative to Coumadin which, while effective at thinning blood for the prevention of stroke and other cardiovascular issues, required frequent and consistent monitoring of blood and diet in order to prevent bleeding issues. An ace doctors possessed in dealing with an unexpected bleeding issue involving Coumadin was vitamin K which, when administered, quickly reversed the thinning properties of warfarin and thereby reducing potentially serious risks to patients.
Xarelto - as many a Xarelto Side Effects lawsuit will attest - was heralded in 2011 as a breakthrough in blood thinning - a product that served as an effective anticoagulant without the need for strict monitoring that was the bastion of warfarin and the bane of both patient and caregiver alike.
However, consumers were surprised to learn in the face of a serious Xarelto Bleedout that such an antidote previously associated with warfarin, would not work with Xarelto - and, in fact, Rivaroxaban was brought to market without one.Initially, a typical Xarelto lawsuit vilified the manufacturer for not properly communicating to consumers and the medical community the lack of an antidote, or so it has been alleged. Since then, an increasing number of lawsuits have taken the manufacturer of Xarelto to task for promoting Xarelto as requiring less monitoring than warfarin. Plaintiffs hold that given the lack of an antidote when Xarelto was brought to market, the need for monitoring was even more important - and thus promoting a need for less monitoring may have been irresponsible.
A recent Xarelto Death lawsuit profiled as part of a release appearing on the website of KEYC News 12 (2/16/16) in Mankato, Minnesota, was filed in the Sunshine State by a resident of South Florida who filed her Xarelto Lawsuit on behalf of her late husband (Case No. 9:14-cv-80831). The plaintiff holds that use of Xarelto caused the death of her husband following an uncontrollable Xarelto Bleeding Issue that proved fatal. Doctors were unable to stem the Xarelto Bleedout, and the man died from a subdural hemorrhage. His widow is alleging wrongful death.
Yet another Xarelto lawsuit was recently filed by Norma Jean and Paul Dunbar, Case No. 2:15-xc-06870, and transferred to multidistrict litigation in Louisiana.https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-36-21300.html
-
Xarelto Lawsuit Plaintiffs Share Their Concerns For Chris Bosh
Feb 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
The NBA team the Miami Heat may once again find themselves short one of their stars if physicians believe that Chris Bosh shouldn’t return to the court.
Bosh was recently pulled out of a game because of concern for a potential blood clot. This isn’t the first time that he has had a scare because of a clot – in 2015, he was taken to the hospital with shortness of breath and chest pains. Doctors determined at that time that he had a pulmonary embolism – a blood clot in the lung. Due to his medical condition, he missed the rest of the season. Doctors placed Bosh on blood thinners for several months before he was weaned off.
It is possible, if he has once again formed a dangerous clot, that they may place him on blood thinners for a second time.
Plaintiff’s Concerns
Of the thousands of lawsuits filed against Bayer AG and Johnson & Johnson regarding the blood thinner Xarelto, many of the plaintiffs are fans of Chris Bosh. They are hoping that his physicians won’t place him on Xarelto because they believe that the drug harms more than it helps.
Xarelto is a new blood thinner that has only been available in the United States since 2011. The U.S. Food and Drug Administration approved the drug for the treatment of clotting disorders, deep vein thrombosis (DVT), atrial fibrillation, and for patients who were at risk for forming blood clots after knee and hip replacement surgeries.
As the manufacturers heavily advertised, this blood thinner was different from the older versions. With Xarelto, all patients are given the same dosages. Other drugs, such as Warfarin, require patients to frequently recheck the clotting factors in their blood to determine if the dosage needs adjusting. Patients and doctors were thrilled that they would no longer have to carefully monitor the blood.
The drug was prescribed to people throughout the country. But what the public was generally unaware of, was that Xarelto has some very dangerous side effects.
The Search For An Antidote
One of the most dangerous aspects of the drug is that it has no known antidote. This means that if uncontrollable bleeding occurs, the blood doesn’t clot appropriately because there is no way to reverse the effects of the drug. Older blood thinners can be reversed by administering Vitamin K, this, however, does not work on Xarelto. If a patient is in danger of losing too much blood, doctors are forced to perform blood transfusions. In some cases, even this treatment isn’t enough to keep the patient from bleeding out and dying.
Other plaintiffs have reported that they suffered from pulmonary embolisms, gastrointestinal bleeding, brain hemorrhage, stroke, spinal bleeding, or liver dysfunction after they began taking the drug.
The FDA has issued not just one, but two, black box warnings. The first indicates that patients who discontinue the drug too quickly are at increased risk for blood clot formation and the second informed those who may be undergoing spinal procedures, that if they are on Xarelto, they are at risk for a spinal bleed.
MDL 2592
So many lawsuits have been filed, each one alleging that Xarelto caused the plaintiff or the loved one of a plaintiff serious harm, that the Judicial Panel on Multidistrict Litigation consolidated all federally filed lawsuits in December of 2014. The purpose of the consolidation was to avoid duplicate discovery and save all parties involved both time and money.
Several pre-trial orders have been announced, including order 15A, which orders the preservation of emails, text messages, and instant messages. As these cases await trial, the litigation is expected to grow.
Plaintiffs are hoping to recover compensation for the money they have spent on medical treatments and for the pain and suffering they have experienced. They also hope that by raising awareness, they can prevent others, like Chris Bosh, from experiencing the trauma that they have.
http://bloodthinnerhelp.com/xarelto-lawsuit-plaintiffs-share-their-concerns-for-chris-bosh/
-
Xarelto Caused Gastrointestinal Bleeding, Lawsuit Says
Mar 2, 2016 | Top Class Actions
By Ashley Vanover
Although Xarelto was approved for use in 2011 and is one of the newest blood thinners on the market, it is already the subject of claims and litigation carrying allegations that the blood thinner puts patients at risk for dangerous side effects, including life-threatening internal bleeding.
In fact, in one recently filed blood thinner lawsuit joining the multidistrict litigation against the makers of Xarelto, Bayer Healthcare and Janssen Pharmaceuticals, several plaintiffs collectively claim that the drug caused serious bleeding events and even death.
In the Xarelto blood thinner lawsuit, one plaintiff, John O., alleges the companies downplayed the risk of serious gastrointestinal bleeding caused by the blood thinner, accusing the drug makers of deliberately concealing the potentially fatal side effect.
According to the blood thinner lawsuit, John used Xarelto as prescribed for approximately 15 months from April 2013 until July 2014 when he then experienced side effects of Xarelto that led to serious gastrointestinal bleeding.
John claims the drug should not be sold and that Bayer and Janssen negligently promoted Xarelto as safe when they allegedly knew the blood thinner could cause serious gastrointestinal bleeding.
Side Effects of Xarelto
Xarelto (rivaroxaban) was first approved by the FDA in July of 2011 as a prescription medicine with three primary uses: to reduce the risk of blood clots and stroke in patients with atrial fibrillation, to treat deep vein thrombosis and pulmonary embolism, and to reduce the risk of blood clots in patients undergoing knee or hip replacement surgery.
Xarelto belongs to a class of anticoagulants called direct factor Xa inhibitors. Sometimes referred to as blood thinners, anticoagulants interfere with the normal clotting of the blood.
Clotting is essential if a person is to stop bleeding from an open wound, but some people experience clotting when they are not injured. Atrial fibrillation is a heart condition characterized by an irregular heartbeat that can cause blood to pool in the heart and may lead to clots.
If the clots travel to the brain, they may cause a stroke. Blood clots that develop in the legs (deep vein thrombosis) and pulmonary embolism (blood clots in the lungs) can also cause serious complications and/or death if left untreated.
Signs of Gastrointestinal Bleeding
When taking an anticoagulant drug like Xarelto, gastrointestinal bleeds can occur both in the upper and lower GI tract, posing a serious risk to the patient. If left untreated, the gastrointestinal bleed may continue unabated, ultimately reaching a critical point when blood loss becomes severe.
Regarded as a relatively common complication of Xarelto, gastrointestinal bleeding can result in hospitalization and in some cases, death.
Signs of gastrointestinal bleeding associated with Xarelto can take a number of different forms, including:abdominal pain
a hard abdomen
vomiting blood
bloody stool
black, tar-like stool
very pale complexion
extreme tiredness
fainting
Xarelto users experiencing the above signs of gastrointestinal bleeding should seek medical treatment immediately.
Xarelto Lawsuits
The FDA reports that more than 1,800 adverse events have been linked to the blood thinner. The most common side effects of Xarelto reported were pulmonary embolism (386 reports), deep vein thrombosis (279 reports), serious gastrointestinal bleeding (107 reports) and hemorrhage (107 reports). Hospitalization was reported in 891 of these events, and 183 of the patients lost their lives.
If you or a loved one has experienced serious gastrointestinal bleeding or other side effects of Xarelto, it is critical to understand your legal rights in order to recover for any damages suffered.
An experienced Xarelto attorney can carefully evaluate the facts of your particular situation and effectively pursue appropriate legal action to fully compensate you for your losses, including medical expenses, lost wages, therapy costs, emotional distress, and wrongful death.
The Xarelto Lawsuit is part of the Xarelto MDL known as In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/328530-328530/
-
Xarelto® (Rivaroxaban) & Bleeding Lawsuits
Mar 2, 2016 | Peterson and Associates
Did Xarelto cause excessive bleeding? Call our drug injury lawyers!
Xarelto® (rivaroxaban) is a medication jointly produced by pharmaceutical giants Bayer and Johnson & Johnson. The drug was released to the market in 2011 and the FDA approved it as a blood-thinner that is used to treat patients in danger of experiencing strokes.
However, despite its recent entry into the consumer drug market, Xarelto has already been linked to a number of serious injuries, including blood clots—which are known to cause a blockage in the veins and potentially result in a fatality.
If you are among those affected by Xarelto, don’t hesitate to call our Kansas City dangerous drug attorneys at (816) 298-8708.
Side Effects of Xarelto
Individuals who were prescribed Xarelto have been known to suffer from a series of negative side effects and ailments that have included nose bleeds, muscle pain, dizziness, and vomiting. Younger patients were given this drug to act as a coagulant after hip replacement or knee surgery; many of those users experienced severe blood clotting that resulted in other, serious health consequences.
Many of the side effects of the anticoagulant can cause serious injuries, including:Internal bleeding
Brain hemorrhages
Stroke
Fatal bleeding
Unfortunately, these injuries are not uncommon in patients who have been prescribed Xarelto. There are even some studies that demonstrate that the drug may not increase survival rates in patients.
Xarelto Lawsuits
The first Xarelto bleeding lawsuit was filed in 2014 by a woman who suffered severe gastrointestinal bleeding and was hospitalized. She claims Bayer and Johnson & Johnson knew the dangers of the medicine, but did not properly inform the public. More lawsuits are expected as people become more aware of the drug’s side effects.Suffered Side Effects from Xarelto? Let Us Help.
At Peterson & Associates, we are a team of committed advocates who assert the rights of patients who have been treated poorly. Our founding attorney, David Peterson, has decades of experience assisting clients from over 20 states and has resolved many mass tort pharmaceutical and product liability cases.
Our team of highly trained drug injury lawyers in Kansas has experience assessing individual drug lawsuits and potential class action lawsuits related to the harmful impact of Xarelto.
http://www.petersonlawfirm.com/dangerous-drugs/xarelto/
-
Monsanto Roundup Lawsuit Alleges Non-Hodgkin’s Lymphoma Diagnosis Caused by Exposure
Mar 3, 2016 | AboutLawsuits.com
By Irvin Jackson
A farm worker diagnosed with non-Hodgkin lymphoma following Roundup exposure has filed a product liability lawsuit against Monsanto, alleging that the multinational agricultural biotechnology corporation withheld information about the cancer risks associated with their popular herbicide.
The complaint (PDF) was filed by Aaron Johnson in the U.S. District Court of Hawaii on February 19, indicating that he was expose to the glyphosate-based herbicide while working on a Macadamia farm in the state and while clearing land.
Johnson indicates that he was diagnosed with non-Hodgkin lymphoma in January 2014, after years of mixing and applying Roundup to and around crops. As a result of the cancer allegedly caused by side effects of Roundup, Johnson has since had to undergo harsh radiation and chemotherapy, maintaining that his life has been irreversibly altered.
“For nearly 40 years, farms across the world have used Roundup without knowing of the dangers its use poses,” the lawsuit filed by Johnson states. “That is because when Monsanto first introduced Roundup, it touted glyphosate as a technological breakthrough: it could kill almost every weed without causing harm either to people or to the environment. Of course, history has shown that not to be true.”
In March 2015, the International Agency for Research on Cancer (IARC), an arm of the World Health Organization (WHO), warned that glyphosate probably causes cancer in humans, raising questions about the safety of Monsanto’s widely used Roundup weedkiller. The IARC specifically noted that non-Hodgkin lymphoma is a form of cancer that may be connected to Roundup and other glyphosate-based weedkillers.
The case is one of a growing number of Monsanto Roundup lawsuits filed in recent months by individuals throughout the U.S. who were heavily and regularly exposed to glyphosate contained in the popular weedkiller as farm workers, landscapers, gardeners or others in the agricultural business.
Plaintiffs allege that Monsanto knew or should have known for decades about the Roundup cancer risks, yet failed to warn consumers about the risks and the importance of taking precautions while using the weedkiller.
Roundup is one of the most widely used herbicides containing glyphosate, which was first introduced by Monsanto in the 1970s.
A recent U.S. Geological Survey on glyphosate usage nationwide found that an estimated 2.6 billion pounds of the herbicide has been sprayed on America’s agricultural land over the two decades since the mid-1990s, when Monsanto introduced “Roundup Ready” crops that are designed to survive being sprayed with glyphosate, killing the weeds but not the crops.
As Roundup injury lawyers continue to review and file cases for individuals throughout the U.S. who have been diagnosed with non-Hodgkin’s lymphoma or other forms of cancer, it is ultimately expected that Monsanto will face several thousand complaints in courts throughout the U.S.
http://www.aboutlawsuits.com/monsanto-lymphoma-lawsuit-95813/#sthash.ZMGl7pYJ.dpuf
-
Xarelto Side Effects & Lawsuit Information
Mar 3, 2016 | Active Health News
Xarelto is a blood-thinning drug, or anticoagulant. The U.S. Food and Drug Administration (FDA) approved Xarelto in July 2011, and its sales have steadily grown since then. While bleeding is a common complication associated with anticoagulants, it has been alleged that Xarelto is more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning side effects.
Xarelto Bleeding Lawsuit
Many patients who suffered Xarelto bleeding-related injuries, strokes, pulmonary embolisms, deep vein thrombosis, and heart attacks have filed a Xarelto bleeding lawsuit. Most of these Xarelto bleeding lawsuits are product liability bleed lawsuits against the manufacturers Johnson & Johnson and Janssen Pharmaceuticals. The manufacturers of other, similar blood-thinning drugs face similar Xarelto bleeding lawsuits. Thousands have filed Xarelto bleeding lawsuits against Boehringer Ingelheim. These lawsuits are quite similar and more numerous, and may provide an early glimpse of the future of Xarelto bleeding lawsuits.
While people file lawsuits for many reasons, the most prominent reason is to recover financial compensation for a patient’s injuries. Xarelto injuries can require lengthy hospitalization, significant long-term health care costs, and substantial time away from work. Product liability Xarelto bleeding lawsuits exist in large part to shift the burden of these costs to manufacturers. For many families, filing a Xarelto bleeding lawsuit can be the difference between financial hardship and making ends meet.
Xarelto Bleeding Attorney
Patients who are injured from Xarelto side effects should consult with a Xarelto bleeding attorney to learn more about their legal options. The Rottenstein Law Group is a great Xarelto bleeding attorney who are reviewing claims of uncontrollable Xarelto bleeding side effects that might give rise to Xarelto bleeding lawsuits.Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several xarelto lawsuits from a leading Xarelto bleeding attorney alleging that Xarelto side effects are dangerous and defective. Plaintiffs in the Xarelto bleeding lawsuit allege serious and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug Xarelto. If you or a loved one suffered from one or more of these Xarelto side effects while taking Xarelto, and you wish to discuss your case with a Xarelto bleeding attorney.
What are the Side Effects of Xarelto?
Xarelto Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects of Xarelto when taking this medication.
Xarelto side effects include easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), bleeding from wounds or needle injections, any bleeding that will not stop. Heavy menstrual periods is a dangerous Xarelto side effect. Other Xarelto side effects include black or bloody stools, coughing up blood or vomit that looks like coffee grounds.
Less serious Xarelto side effects may include: muscle pain, itching and pain in arms or legs. However, the most common adverse Xarelto side effects are bleeding complications, including major bleeding events. Fainting, itching, and muscle spasms have been reported. Some blood thinning antibiotics, antifungal medications, anticoagulants, blood thinners, NSAIDs, and aspirin may have adverse interactions and cause further Xarelto side effects.
http://activehealthnews.com/xarelto-side-effects-lawsuit-information/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested